Introduction
============

Tamoxifen, a selective estrogen receptor modulator, has been used as adjuvant therapy in breast cancer patients with hormone receptor-positive tumors for decades. Five years of oral tamoxifen treatment reduces the risk of cancer recurrence by \~60%. However, up to 40% of patients who receive tamoxifen experience distant or local recurrence, or die.[@b1-ott-9-2121],[@b2-ott-9-2121] Tamoxifen undergoes extensive metabolism by the CYP2D6 enzyme in the liver leading to the formation of more pharmacologically active metabolites, 4-hydroxyta-moxifen and endoxifen.[@b3-ott-9-2121] *CYP2D6* polymorphisms have been extensively studied for the pharmacogenetic association in breast cancer patients treated with tamoxifen. However, several lines of inconsistent evidence have been reported.[@b4-ott-9-2121]--[@b14-ott-9-2121] In addition to CYP2D6, CYP3A5 is another enzyme involved in tamoxifen metabolism. The impact of *CYP3A5* 6986A\>G on the treatment outcome of tamoxifen has been studied, however, the results are controversial.[@b15-ott-9-2121]--[@b18-ott-9-2121]

Tamoxifen active metabolites, 4-hydroxytamoxifen and endoxifen, have been established to bind with the ABC subfamily B member 1.[@b19-ott-9-2121] ABCB1 is an active drug efflux transporter. It is a multiple drug resistance transporter, which may act as a barrier and limit the accessibility of active metabolites of tamoxifen to various critical target tissues. Recently, *ABCB1* 3435C\>T has been demonstrated to be associated with increased risk of recurrence in Asian women who received tamoxifen.[@b20-ott-9-2121] In addition to ABCB1, overexpression of ABCC2, efflux transporter, was observed in tamoxifen-resistant breast cancer cells.[@b21-ott-9-2121] Interestingly, a polymorphism of the *ABCC2* gene has been associated with 5-year tamoxifen treatment outcomes in Japanese subjects with breast cancer.[@b8-ott-9-2121] Therefore, genetic variants of these metabolizing enzymes and drug transporters are likely to play a role to a variable degree in the clinical outcome of tamoxifen treatment. Our earlier study reported the impact of *ABCB1* polymorphism on 3-year tamoxifen effectiveness in Thai populations.[@b22-ott-9-2121] However, the impact of clinical prognostic factors and genetic variants that contributed to 5-year tamoxifen effectiveness in Thai populations has never been evaluated. In this study, genetic variants of *CYP3A5* (6986A\>G), *CYP2D6* (100C\>T), *ABCB1* (3435C\>T), and *ABCC2* (−24C\>T) in Thai breast cancer patients were investigated. The retrospective analysis of patients with primary breast cancer who developed distant metastatic disease during tamoxifen treatment was conducted. The risk of distant metastasis within 5 years was evaluated by using clinical and genetic prognostic factors in terms of organ-specific metastasis and associated patient outcomes.

Materials and methods
=====================

Patient selection criteria
--------------------------

Thai patients with primary breast cancer who visited Ramathibodi Hospital, Bangkok, Thailand, during the period between February 1997 and January 2008 were selected for this study. The inclusion criteria for this study were: age ≥18 years, non-pregnant women, histological confirmation of primary breast cancer with estrogen receptor (ER)^+^ and/or progesterone receptor (PR)^+^ testing, received 20 mg/day tamoxifen as an adjuvant treatment for breast cancer. In addition, all subjects were selected with regard to the consistency of pathological parameters including stage of the cancer, fundamental characteristics for the existence of metastasis and evolution of the pathology. Exclusion criteria included concurrent medications that induce or inhibit CYP2D6, CYP3A4/5, and efflux transporters. The study was approved by Ethics Committee of Ramathibodi Hospital and written informed consent was obtained from all patients. According to our criteria, the retrospective study was conducted in 73 breast cancer patients. All patients were pathologically diagnosed with invasive breast cancer without distant spread. Most patients were treated with a modified radical mastectomy. The regimens of adjuvant chemotherapy which are composed of cyclophosphamide, methotrexate, and 5-fluorouracil, adriamycin based, and adriamycin-taxane based regimens were given to nearly all patients. Thirty patients were treated with radiation. The median follow-up time of all patients was 5 (range 0.2--14.3) years.

Sample preparation and genotyping
---------------------------------

Blood samples were collected (5 mL) in ethylenediaminetetraacetic acid tubes and stored at −20°C until isolation of genomic DNA for genotype analysis. All samples were isolated with phenol-chloroform method. DNA purity was assessed by using NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Inc., Wilmington, DE, USA).

In this study, candidate gene approach based on tamoxifen pharmacokinetics was performed. All selected variants are single-nucleotide polymorphisms (SNPs) that can affect protein function or expression. The rationale for selecting each is described as follows. As mentioned earlier, hepatic CYP2D6 plays a major role in tamoxifen biotransformation. The common reduced-activity allele in Asians is *CYP2D6\*10* where as *CYP2D6\*4*, a non-functional allele, is commonly found in Caucasians.[@b23-ott-9-2121],[@b24-ott-9-2121] *CYP2D6* 100C\>T, being part of both *CYP2D6\*4* and *CYP2D6\*10* haplotypes, is likely to be the causative SNP for the reduced function of *CYP2D6\*10*.[@b25-ott-9-2121] *CYP3A5\*3* (6986A\>G), a non-expressor allele, has been reported to be involved in variable metabolism of CYP3A5 substrates, including tamoxifen.[@b23-ott-9-2121] *ABCB1* 3435C\>T is the common SNP associated with altered P-gp expression and/or function.[@b26-ott-9-2121] Recently, it was reported that ABCB1 could transport endoxifen out of the blood--brain barrier in an animal model.[@b19-ott-9-2121] The overexpression of ABCC2 has been found in tamoxifen-resistant breast cancer cells.[@b21-ott-9-2121] Thus, the possibility that active metabolites could be pumped out from breast cancer cells by ABCB1 and ABCC2 has been suggested. The genotype of each candidate SNP was determined using Taqman drug metabolism genotyping assays (Thermo Fisher Scientific, Waltham, MA, USA) as follows: *ABCB1* (3435 C\>T) (Assay ID: C\_\_7586657_20), *ABCC2* (−24C\>T) (Assay ID: C\_\_2814642_10), *CYP3A5* (6986A\>G) (Assay ID: C\_\_26201809_30) and *CYP2D6* (100C\>T) (Assay ID: C\_\_11484460_40). The genotyping experiments were carried out by using real-time polymerase chain reaction Viia™ 7 instrument and performed according to manufacturer's protocol.

Statistical analysis
--------------------

The impact of clinical and genetic prognostic factors in breast cancer patients treated with 5-year tamoxifen was evaluated in terms of overall and organ-specific metastases. Disease-free survival (DFS) time was defined as the period from starting date of tamoxifen to the date of first disease recurrence (distant recurrence). Patients who had lived without disease recurrence for 5 years were defined as the non-metastasis group, whereas patients who had relapsed within 5 years were defined as the metastasis group. In this study, Fisher's exact test was used to test the difference of clinical parameters and genotype frequency between metastasis and non-metastasis groups. Then, the difference of DFS estimated by Kaplan--Meier method across genotypes was examined by log-rank test. Cox proportional hazard analysis was used to identify significant clinical prognostic factors and to test for an independent contribution of genetic factors to the variable outcomes. Multivariate analysis was evaluated by step-wise forward Cox's regression analysis. The result was considered to be statistically significant when bilateral *P*-values were \<0.05. Statistical tests were performed using Stata software version 12 (StataCorp LP, College Station, TX, USA).

Results
=======

The comparison of patient characteristics
-----------------------------------------

All patients were estrogen receptor positive and were recommended to receive 5-year adjuvant tamoxifen therapy. Their median age at the time of surgery was 50 years old (range 28--76). The median follow-up time of non-metastasis was 87.6 months (range 60--171.6). The median follow-up time of bone, lung, and liver metastasis group was 48.0 months (range 2.0--172.0), 93.5 months (range 59.0--172.0), and 22.0 months (range 2.0--62.0), respectively. The number of pre- and postmenopausal patients was 47 and 26, respectively. The comparisons of clinical prognostic factors between non-metastasis and metastasis group according to first disease metastasis are shown in [Table 1](#t1-ott-9-2121){ref-type="table"}.

Bone metastasis was found more frequently in premenopausal patients than in postmenopausal patients, but the difference did not reach statistical significance (*P*-value =0.099). In addition, a number of patients with tumor size \>5 cm also showed incidence of metastasis to lung and liver. A significant difference was found in the lung metastasis group, but not in the liver metastasis group (*P*-value =0.033 and 0.084, respectively).

Associations between genotypes and clinical outcomes
----------------------------------------------------

*ABCB1* 3435C\>T, *ABCC2* −24C\>T, *CYP3A5* 6986A\>G, and *CYP2D6* 100C\>T were successfully genotyped in all patients. The genotype frequencies of these variants were compared between non-metastasis and metastasis groups according to first dominant site of metastasis as shown in [Table 2](#t2-ott-9-2121){ref-type="table"}. There was no significant difference between genotype frequency and first dominant site of metastasis. Regardless of any first dominant site of metastasis, Kaplan--Meier analysis indicated that patients carrying *ABCC2* −24*CC* had significantly shorter DFS than those who carry −24*CT* (log-rank test, *P*=0.044; [Figure 1](#f1-ott-9-2121){ref-type="fig"}). Regarding bone metastasis, patients carrying *ABCC2* −24*CC* and *ABCB1* 3435*CT* or *TT* genotypes had significantly shorter DFS time than those who carry *ABCB1* 3435*CC* and *ABCC2* −24*CC* or *ABCC2* −*24CT* (log-rank test, *P*=0.040; [Figure 2](#f2-ott-9-2121){ref-type="fig"} and [Table S1](#SD1-ott-9-2121){ref-type="supplementary-material"}). No such variants of *CYP3A5* 6986A\>G and *CYP2D6* 100C\>T were found to be associated with tamoxifen treatment outcomes.

Correlation of prognostic clinical factors and pharmacogenetic factors with the risk of distant metastasis
----------------------------------------------------------------------------------------------------------

In the univariate Cox proportional hazard analysis for distant metastasis-free survival, only tumor size \>5 cm was considered to be a significant associated factor (*P*=0.004; hazard ratio, 3.05; 95% confidence interval, 1.44--6.47, [Table 3](#t3-ott-9-2121){ref-type="table"}). In the multivariate analysis, tumor size \>5 cm remained predictive of distant metastasis after adjustment for age, menstrual status, lymph node status, and pharmacogenetic factors (*P*\<0.001; adjusted hazard ratio, 5.49; 95% confidence interval, 2.30--13.10). Moreover, the *ABCC2* genotype (*CT* vs *CC*) was shown to be associated with increased risk of distant metastasis in 5-year tamoxifen treatment after adjustment for age, menstrual status, tumor size, and lymph node status (*P*=0.040; adjusted hazard ratio, 2.34; 95% confidence interval, 1.04--5.27 for *ABCC2 CC*). Nevertheless, the combined genotype of *ABCB1* and *ABCC2* (other combined genotypes vs *ABCC2 CC − ABCB1 CT*+*TT*) was shown to be associated with increased risk of distant metastasis after adjustment for age, menstrual status, tumor size, and lymph node status (*P*=0.020; adjusted hazard ratio, 2.46; 95% confidence interval, 1.15--5.26 for *ABCC2 CC − ABCB1 CT*+*TT*).

Regarding bone metastasis, none of the prognostic clinical factors were shown to be associated with an increased risk of recurrence in both univariate and multivariate analysis ([Table 4](#t4-ott-9-2121){ref-type="table"}). Unexpectedly, the combined genotype of *ABCC2* −24*CC* and *ABCB1* 3435*CT* or *TT* was significantly correlated with increased bone metastasis risk after adjustment for age, menstrual status, tumor size, and lymph node status (*P*=0.040; adjusted hazard ratio, 3.70; 95% confidence interval, 1.06--12.89 for *ABCC2 CC − ABCB1 CT*+*TT*, [Table 4](#t4-ott-9-2121){ref-type="table"}).

Regarding lung and liver metastasis, tumor size was the only prognostic factor that significantly contributed to shorter DFS in both univariate and multivariate analyses (data not shown).

Discussion
==========

In developing countries, the majority of breast cancer occurs among premenopausal women with a mean age of 50.[@b27-ott-9-2121] Five-year treatment with tamoxifen is the main endocrine therapy for premenopausal women with ER^+^ breast cancer. In postmenopausal women only, aromatase inhibitor (AI) treatment offers more benefits than tamoxifen by greatly reducing estrogen concentrations, hence avoiding stimulation of ER^+^ breast cancer cells.[@b28-ott-9-2121] However, postmenopausal patients with intolerance to AIs could switch to tamoxifen after at least 2 years of treatment with AIs.[@b29-ott-9-2121] The variability in tamoxifen response among ER^+^ individuals is consistently observed. It is mainly caused by the differences in various clinical prognostic factors and characteristics of the tumor. Since genomic knowledge is becoming increasingly relevant, prognosis and breast cancer treatment could be partly explained by pharmacogenomics.

CYP2D6 plays a major role in the conversion of tamoxifen to endoxifen, which is the most potent anti-estrogen metabolite.[@b30-ott-9-2121] *CYP2D6\*10*/\**10*, a common reduced-activity allele in Asians including Thais, was demonstrated to be associated with significantly lower endoxifen level compared to *CYP2D6\*1*/\**1* at steady-state of tamoxifen adjuvant therapy.[@b8-ott-9-2121],[@b31-ott-9-2121],[@b32-ott-9-2121] Consequently, Asian women carrying *CYP2D6\*10/\*10* genotype had significantly shorter DFS than those who carry *CYP2D6\*1/\*1* genotype treated with the equivalent dose of tamoxifen.[@b6-ott-9-2121],[@b7-ott-9-2121],[@b10-ott-9-2121],[@b31-ott-9-2121] Furthermore, *CYP2D6\*10/\*10* was independently correlated to unfavorable outcomes in tamoxifen treatment, significant in the multivariate analyses adjusted for clinical prognostic factors.[@b7-ott-9-2121],[@b31-ott-9-2121] The pharmacogenetic association of *CYP2D6* and tamoxifen is mostly observed in the retrospective study, however, two prospective clinical trials recently showed that *CYP2D6* genotypes were not able to predict clinical benefit of tamoxifen treatment.[@b11-ott-9-2121],[@b12-ott-9-2121] In addition, they found that *CYP2D6* alleles predicting reduced and deficient enzyme activities were correlated with increased side effects, such as hot flushes, rather than the variation of tamoxifen effectiveness. A high level of tamoxifen still poses clinically significant adverse effects, such as thromboembolic events and endometrial cancer. However, a low endoxifen level might unchangingly exert an anti-estrogen effect, as indicated by Ki-67 proliferative index that was observed in patients who received low-dose tamoxifen treatment.[@b33-ott-9-2121] There is only one piece of evidence that supports the association of *CYP3A5\*3/\*3* representing an inactive form of the enzyme and favorable response to tamoxifen.[@b18-ott-9-2121] However, homozygous *CYP3A5\*3* has never been shown to be associated with endoxifen level, or even to increase the risk of recurrence in women prescribed tamoxifen.[@b22-ott-9-2121],[@b23-ott-9-2121] In our study, we did not find any associations of *CYP2D6\*10* (100C\>T) and *CYP3A5\*3* (6986A\>G) with an increased risk of 5-year recurrence in Thai patients with early breast cancer receiving adjuvant tamoxifen.

Apart from metabolizing enzymes, drug transporter polymorphisms have been addressed in an issue of tamoxifen-outcome variation. Japanese women carrying wild-type allele *ABCC2* 68231A\>G were associated with an increased risk of recurrence during adjuvant tamoxifen therapy.[@b6-ott-9-2121] Homozygous *CC* genotype of *ABCB1* 3435C\>T was recently shown to correlate with shorter DFS in Asian breast cancer patients treated with tamoxifen.[@b20-ott-9-2121] Noticeably, both studies demonstrated the significance of drug transporter genes with wild-type allele when analyses were performed in combination with impaired or absent functional variants of *CYP2D6*. The consistent results may reflect the important role of drug transporters in limiting intracellular drug concentration caused by defective hepatic CYP2D6. However, we could not determine the combined genotype of drug metabolizing enzyme (*CYP3A5*, *CYP2D6*) and drug transporter (*ABCC2*, *ABCB1*) polymorphisms affecting either DFS or recurrence risk even in subgroup analysis.

Indeed, the association of the combined genotype, *ABCC2* −24C\>T and *ABCB1* 3435C\>T, with tamoxifen treatment outcomes was unexpectedly discovered. The combination of *ABCC2* −24*CC* and *ABCB1* 3435*CT*+*TT*, along with tumor size, was displayed to be associated with increased risk of 5-year distant metastasis in Thai patients with ER^+^ breast cancer receiving adjuvant tamoxifen. In general, tumor size and lymph node status are the fundamental predictors of prognosis in solid cancers. However, most of our patients with bone metastasis had small size primary tumors and less lymph node involvement, hence, their recurrence risk could not be estimated by clinical prognostic factors. Nevertheless, pharmacogenetic factors served as predictive markers for them due to the combined genotype of drug transporters which exclusively expressed the significant association. Homozygous wild-type *ABCC2* −24C\>T and *ABCB1* 3435C\>T were associated with increased efflux protein expression, which may result in the reduction of active tamoxifen metabolites' bioavailability in patients, at both intracellular and plasma levels, finally, leading to treatment failure.[@b34-ott-9-2121]--[@b36-ott-9-2121] As mentioned above, homozygous wild-type *ABCC2* −24C\>T and *ABCB1* 3435C\>T need to be combined with reduced or non-functional variants of CYP2D6 predicted phenotype to increase risk of recurrence. Because of our limitations, not all of the variants for CYP2D6 phenotype prediction were determined, thus, we could not reveal any such association. However, our results are partly consistent with the hypothesis regarding the significant association of *ABCC2* −24*CC* with short DFS. Interestingly, some reports gave us a clue that the effects of *ABCB1* 3435C\>T may be exerted differently in an organ-specific manner. In Asian studies, *ABCB1* 3435*TT* genotype was revealed to be associated with high risk of death from osteosarcoma,[@b37-ott-9-2121] while breast cancer patients carrying the same *TT* genotype had a favorable prognosis.[@b38-ott-9-2121] Standard chemotherapy regimens were prescribed in both studies. Thus, it may be postulated that *ABCB1* 3435*TT* genotype "prefers" to facilitate drug therapy against breast tumors in contrast to bone tumors. Nevertheless, it could be speculated that there is an organ-specific association in a case of drug resistant epilepsy where *ABCC2* −24*CC* genotype was significantly correlated with responders.[@b39-ott-9-2121] In contrast, it was found that *ABCC2* −24*CC* genotype was associated with tamoxifen non-responders in breast cancer patients in this study and a previous one.[@b20-ott-9-2121] The organ-specific effects of *ABCB1* and *ABCC2* polymorphisms might be underestimated and need to be proved.

According to multivariate analysis, *ABCC2* −24*CC* and *ABCB1* 3435*CT*+*TT* were significantly associated with bone metastasis adjusted for age, menstrual status, tumor size, and lymph node status. However, both markers need to be verified in a prospective study with a large sample size. Tamoxifen monotherapy should be the inclusion criteria because adjuvant chemotherapy followed by tamoxifen was associated with bone loss in premenopausal patients, and thus could confound the study outcome.[@b40-ott-9-2121] In addition, all of the predicted CYP2D6 phenotypes and other significant prognostic factors must be completely determined to confirm validation of our results.

Conclusion
==========

This finding presented the prognostic value of pharmacogenetic factors in adjuvant tamoxifen therapy where conventional factors were weakly predictive of breast cancer prognosis. The combined genotype of *ABCC2* −24C\>T and *ABCB1* 3435C\>T was indicated for the increased risk of specific disease recurrence such as bone metastasis. Novel prognostic factors are needed to improve the clinical outcomes for all breast cancer patients treated with tamoxifen. The incorporation of pharmacogenetic tests into routine clinical practice is also necessary for the development of a health care system in Thailand.

Supplementary material
======================

###### 

A combination of the *ABCC2* and *ABCB1* genotypes and bone-metastasis-free survival profile of individual patients

  Patient number   Combined genotypes of *ABCC2* −24C\>T and *ABCB1* 3435C\>T   DFS time (years)
  ---------------- ------------------------------------------------------------ ------------------
  1                −24CT +3435TT                                                7.8
  2                −24CC +3435CC                                                5.7
  3                −24CC +3435TT                                                9.8
  4                −24CT +3435CC                                                6.1
  5                −24CT +3435CT                                                8.6
  6                −24CC +3435CC                                                10.2
  7                −24CC +3435CC                                                6.8
  8                −24CT +3435TT                                                8.3
  9                −24CT +3435CT                                                7.9
  10               −24CT +3435CC                                                8.9
  11               −24CC +3435CT                                                5.6
  12               −24CC +3435CC                                                7.3
  13               −24CC +3435CC                                                5.2
  14               −24CC +3435CC                                                10.1
  15               −24CT +3435TT                                                5.0
  16               −24CC +3435CT                                                8.9
  17               −24CT +3435TT                                                8.9
  18               −24CT +3435CT                                                10.5
  19               −24CT +3435CC                                                14.3
  20               −24CT +3435CT                                                7.3
  21               −24CC +3435CC                                                8.4
  22               −24CT +3435CC                                                5.1
  23               −24CT +3435CT                                                5.0
  24               −24CC +3435CT                                                5.0
  25               −24CT +3435TT                                                8.1
  26               −24CT +3435CC                                                10.3
  27               −24CT +3435CC                                                7.3
  28               −24CC +3435CC                                                5.6
  29               −24CC +3435CT                                                6.2
  30               −24CC +3435CT                                                11.4
  31               −24CC +3435CT                                                5.8
  32               −24CT +3435TT                                                5.5
  33               −24CC +3435CT                                                5.6
  34               −24CT +3435CT                                                5.5
  35               −24CC +3435CC                                                7.5
  36               −24CT +3435CT                                                5.2
  37               −24CC +3435CC                                                5.4
  38               −24CT +3435CC                                                5.5
  39               −24CC +3435TT                                                11.8
  40               −24CC +3435CT                                                4.6
  41               −24CC +3435TT                                                4.5
  42               −24CC +3435CT                                                3.8
  43               −24CC +3435CC                                                3.0
  44               −24CC +3435TT                                                2.7
  45               −24CC +3435CT                                                1.2
  46               −24CC +3435CT                                                0.6
  47               −24CT +3435CT                                                1.2
  48               −24CC +3435CT                                                0.5
  49               −24CT +3435CT                                                1.8
  50               −24CC +3435CC                                                1.3
  51               −24CC +3435CC                                                1.0
  52               −24CT +3435CT                                                2.1

**Abbreviation:** DFS, disease-free survival.
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![The Kaplan--Meier survival curve compares 46 patients carrying *ABCC2* −24*CC* to 27 patients carrying *ABCC2* −24*CT* in all groups of distant metastasis with respect to disease-free survival (DFS).](ott-9-2121Fig1){#f1-ott-9-2121}

![The Kaplan--Meier survival curve compares 16 patients carrying *ABCB1* 3435*CT* or *TT* and *ABCC2−*24*CC* to 36 patients carrying other combined genotypes of *ABCC2* and *ABCB1* in bone metastasis with respect to disease-free survival (DFS).](ott-9-2121Fig2){#f2-ott-9-2121}

###### 

The comparisons of clinical characteristics between non-metastasis and metastasis group according to first disease metastasis

  Characteristics                                      Non-metastasis (n=39)   First disease metastasis (n=34)                                                                                       
  ---------------------------------------------------- ----------------------- --------------------------------- ------- ------------ -------------------------------------------------- ----------- -------
  Age at diagnosis; years                                                                                        0.110                1.000                                                          1.000
   ≤50                                                 19 (48.7)               10 (76.9)                                 7 (53.9)                                                        4 (50.0)    
   \>50                                                20 (51.3)               3 (23.1)                                  6 (46.1)                                                        4 (50.0)    
  Menstrual status                                                                                               0.099                0.523                                                          1.000
   Pre-menopause                                       22 (56.4)               11 (84.6)                                 9 (69.2)                                                        5 (62.5)    
   Post-menopause                                      17 (43.6)               2 (15.4)                                  4 (30.8)                                                        3 (37.5)    
  Tumor size; cm                                                                                                 0.632                0.033[\*](#tfn4-ott-9-2121){ref-type="table-fn"}               0.084
   ≤5                                                  35 (89.7)               11 (84.6)                                 8 (61.5)                                                        5 (62.5)    
   \>5                                                 4 (10.3)                2 (15.4)                                  5 (38.5)                                                        3 (37.5)    
  Lymph node status                                                                                              0.518                0.198                                                          0.437
   Positive                                            21 (53.9)               9 (69.2)                                  10 (76.9)                                                       6 (75.0)    
   Negative                                            18 (46.1)               4 (30.8)                                  3 (23.1)                                                        2 (25.0)    
  Tumor grading                                                                                                  0.640                0.150                                                          1.000
   1                                                   6 (26.1)                1 (11.1)                                  0 (0.0)                                                         1 (16.7)    
   2+3                                                 17 (73.9)               8 (88.9)                                  9 (100.0)                                                       5 (83.3)    
   Unknown[b](#tfn2-ott-9-2121){ref-type="table-fn"}   16 (--)                 4 (--)                                    4 (--)                                                          2 (--)      
  LVI[c](#tfn3-ott-9-2121){ref-type="table-fn"}                                                                  0.495                0.717                                                          0.659
   Positive                                            13 (50.0)               4 (36.4)                                  4 (40.0)                                                        2 (33.3)    
   Negative                                            13 (50.0)               7 (63.6)                                  6 (60.0)                                                        4 (66.7)    
   Unknown[b](#tfn2-ott-9-2121){ref-type="table-fn"}   13 (--)                 2 (--)                                    3 (--)                                                          2 (--)      
  ER and/or PR status                                                                                            n/a                  n/a                                                            n/a
   Positive                                            39 (100.0)              13 (100.0)                                13 (100.0)                                                      8 (100.0)   
   Negative                                            0 (0.0)                 0 (0.0)                                   0 (0.0)                                                         0 (0.0)     

**Notes:**

Fisher's exact test;

unknown statuses were excluded from Fisher's exact test;

LVI (lymphovascular invasion) is considered as spreading of cancer to blood vessels and/or lymphatic system.

Statistically significant at *P*-value \<0.05.

**Abbreviations:** ER, estrogen receptor; n/a, not applicable; PR, progesterone receptor.

###### 

The comparisons of pharmacogenetic factors between non-metastasis and metastasis group according to first disease metastasis

  Polymorphisms       Non-metastasis (n=39)   First disease metastasis (n=34)                                          
  ------------------- ----------------------- --------------------------------- ------- ----------- ------- ---------- -------
  *ABCB1* 3435C\>T                                                              0.284               0.841              0.780
   *CC*               17 (43.6)               3 (23.1)                                  5 (38.5)            3 (37.5)   
   *CT*               14 (35.9)               8 (61.5)                                  6 (46.1)            4 (50.0)   
   *TT*               8 (20.5)                2 (15.4)                                  2 (15.4)            1 (12.5)   
  *ABCC2* −24C\>T                                                               0.194               0.194              0.269
   *CC*               20 (51.3)               10 (76.9)                                 10 (76.9)           6 (75.0)   
   *CT*               19 (48.7)               3 (23.1)                                  3 (23.1)            2 (25.0)   
  *CYP3A5* 6986A\>G                                                             0.311               0.707              1.000
   *AA*               24 (61.5)               5 (38.5)                                  8 (61.5)            5 (62.5)   
   *AG*               12 (30.8)               6 (46.1)                                  3 (23.1)            3 (37.5)   
   *GG*               3 (7.7)                 2 (15.4)                                  2 (15.4)            0 (0.0)    
  *CYP2D6* 100C\>T                                                              0.610               0.593              0.474
   *CC*               12 (30.8)               5 (38.4)                                  2 (15.4)            1 (12.5)   
   *CT*               18 (46.1)               4 (30.8)                                  8 (61.5)            4 (50.0)   
   *TT*               9 (23.1)                4 (30.8)                                  3 (23.1)            3 (37.5)   

**Note:**

Fisher's exact test.

###### 

Univariate and multivariate disease-free survival Cox analyses in all breast cancer patients with distant metastasis

  Covariate                                                   Univariate analysis   Multivariate analysis                                                                           
  ----------------------------------------------------------- --------------------- ----------------------- -------------------------------------------------- ------ ------------- ---------------------------------------------------------------------------------------------
  Clinical factors                                                                                                                                                                  
   Age (≤50 vs \>50 years)                                    0.68                  0.34--1.36              0.283                                              0.60   0.27--1.31    0.202
   Menstrual status (post- vs pre-menopause)                  1.77                  0.82--3.80              0.140                                              2.02   0.91--4.48    0.081
   Tumor size (≤5 vs \>5 cm)                                  3.05                  1.44--6.47              0.004[\*](#tfn7-ott-9-2121){ref-type="table-fn"}   5.49   2.30--13.10   \<0.001[\*](#tfn7-ott-9-2121){ref-type="table-fn"}
   Lymph node status (negative vs positive)                   1.84                  0.86--3.95              0.116                                              1.65   0.76--3.59    0.204
  Pharmacogenetic factors                                                                                                                                                           
   *ABCB1* 3435C\>T (*CC* vs *CT*+*TT*)                       1.25                  0.61--2.57              0.540                                              n/a    n/a           n/a
   *ABCC2* −24C\>T (*CT* vs *CC*)                             2.19                  0.99--4.85              0.052                                              2.34   1.04--5.27    0.040[\*](#tfn7-ott-9-2121){ref-type="table-fn"}
   *CYP3A5* 6986A\>G (*AA*+*AG* vs *GG*)                      1.72                  0.60--4.89              0.307                                              n/a    n/a           n/a
   *CYP2D6* 100C\>T (*CC*+*CT* vs *TT*)                       1.22                  0.58--2.55              0.596                                              n/a    n/a           n/a
  Combined genotypes of *ABCB1* and *ABCC2*                                                                                                                                         
   Other combined genotypes vs *ABCC2 CC* − *ABCB1 CT*+*TT*   1.76                  0.89--3.46              0.100                                              2.46   1.15--5.26    0.020[a](#tfn8-ott-9-2121){ref-type="table-fn"},[\*](#tfn7-ott-9-2121){ref-type="table-fn"}

**Notes:**

Statistically significant at *P*-value \<0.05;

*P*-value was calculated from the covariates which were all clinical factors and the combined genotypes of *ABCB1* and *ABCC2*. **Abbreviations:** CI, confidence interval; HR, hazard ratio; n/a, not applicable.

###### 

Univariate and multivariate disease-free survival Cox analyses in breast cancer patients with bone metastasis

  Covariate                                                   Univariate analysis   Multivariate analysis                                
  ----------------------------------------------------------- --------------------- ----------------------- ------- ------ ------------- ----------------------------------------------------------------------------------------------
  Clinical factors                                                                                                                       
   Age (≤50 vs \>50 years)                                    0.33                  0.09--1.19              0.092   0.30   0.07--1.21    0.091
   Menstrual status (post- vs pre-menopause)                  3.59                  0.79--16.22             0.096   4.00   0.86--18.50   0.076
   Tumor size (≤5 vs \>5 cm)                                  1.48                  0.33--6.69              0.610   3.74   0.66--21.08   0.134
   Lymph node status (negative vs positive)                   1.66                  0.51--5.39              0.398   1.31   0.39--4.36    0.658
  Pharmacogenetic factors                                                                                                                
   *ABCB1* 3435C\>T (*CC* vs *CT*+*TT*)                       2.23                  0.61--8.13              0.221   n/a    n/a           n/a
   *ABCC2* −24C\>T (*CT* vs *CC*)                             2.69                  0.74--9.78              0.133   3.16   0.84--11.89   0.088
   *CYP3A5* 6986A\>G (*AA*+*AG* vs *GG*)                      2.20                  0.48--9.98              0.304   n/a    n/a           n/a
   *CYP2D6* 100C\>T (*CC*+*CT* vs *TT*)                       1.51                  0.47--4.92              0.489   n/a    n/a           n/a
  Combined genotypes of *ABCB1* and *ABCC2*                                                                                              
   Other combined genotypes vs *ABCC2 CC* − *ABCB1 CT*+*TT*   2.95                  0.99--8.80              0.051   3.70   1.06--12.89   0.040[a](#tfn10-ott-9-2121){ref-type="table-fn"},[\*](#tfn9-ott-9-2121){ref-type="table-fn"}

**Notes:**

Statistically significant at *P*-value \<0.05;

*P*-value was calculated from the covariates which were all clinical factors and the combined genotypes of *ABCB1* and *ABCC2*. **Abbreviations:** CI, confidence interval; HR, hazard ratio; n/a, not applicable.

[^1]: These authors contributed equally to this work
